ATARA BIOTHERAPEUTICS INC. news, videos and press releases
For more news please use our advanced search feature.
ATARA BIOTHERAPEUTICS INC. - More news...
ATARA BIOTHERAPEUTICS INC. - More news...
- Thinking about buying stock in VinFast Auto, Lilium, Exscientia, Atara Biotherapeutics, or Bird Global?
- Atara Biotherapeutics Announces Second Quarter 2023 Financial Results and Operational Progress
- Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Atara Biotherapeutics to Announce Second Quarter 2023 Financial Results on Tuesday, August 8, 2023
- Atara Biotherapeutics to Participate in the Canaccord Genuity 43rd Annual Growth Conference
- Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Atara Biotherapeutics to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
- Atara Biotherapeutics Presents Updated Tab-cel® Clinical Effectiveness Data at ASCO 2023
- Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Atara Biotherapeutics Announces First Quarter 2023 Financial Results and Operational Progress
- Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Atara Biotherapeutics to Announce First Quarter 2023 Financial Results on Monday, May 8, 2023
- Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 43rd Annual Health Care Conference
- Atara Biotherapeutics to Participate in the H.C. Wainwright Cell Therapy Virtual Conference
- Atara Biotherapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Operational Progress
- Pierre Fabre to Commercialize and Distribute the First Approved Allogeneic T-cell Immunotherapy in Europe Following Transfer of the European Commission Marketing Authorization of EBVALLO™ (tabelecleucel)
- Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results on Wednesday, February 8, 2023
- Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Atara Biotherapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
- Atara Biotherapeutics Announces $31 Million Royalty Interest Financing Agreement with HealthCare Royalty
- Atara Biotherapeutics Announces Changes to Its Board of Directors
- Atara Biotherapeutics' Ebvallo® (tabelecleucel) Receives European Commission Approval as First Ever Therapy for Adults and Children with EBV+ PTLD
- Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) Receives European Commission Approval as First Ever Therapy for Adults and Children with EBV+ PTLD
- Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Atara Biotherapeutics Presents Updated Clinical Data from Pivotal Phase 3 Trial (ALLELE) of Tab-cel® at the 64th American Society of Hematology (ASH) Annual Meeting
- Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Atara Biotherapeutics to Participate at the Evercore ISI 5th Annual HealthCONx Conference